Clinical response to subcutaneous immunotherapy at 3 years in allergic rhinitis patients is predicted by short‐term treatment effectiveness
Main Authors: | Dong Liu, Jingyun Li, Yunbo Gao, Feifei Cao, Wei Xiong, Chengshuo Wang, Yuan Zhang, Luo Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-02-01
|
Series: | Clinical and Translational Allergy |
Online Access: | https://doi.org/10.1002/clt2.12223 |
Similar Items
-
Alternatives to Subcutaneous Immunotherapy for Allergic Rhinitis
by: Tetsuya Terada, et al.
Published: (2022-02-01) -
Long-term efficacy of HDM-SCIT in pediatric and adult patients with allergic rhinitis
by: Lei Ren, et al.
Published: (2023-03-01) -
Safety Profile and Issues of Subcutaneous Immunotherapy in the Treatment of Children with Allergic Rhinitis
by: Anang Endaryanto, et al.
Published: (2022-05-01) -
Metabolomics Reveals Process of Allergic Rhinitis Patients with Single- and Double-Species Mite Subcutaneous Immunotherapy
by: Peiyan Zheng, et al.
Published: (2021-09-01) -
Association between the Interaction of Key Genes Involved in Effector T-Cell Pathways and Susceptibility to Develop allergic Rhinitis: A Population-Based Case-Control Association Study.
by: Yuan Zhang, et al.
Published: (2015-01-01)